Who We Are
Microbion is a clinical-stage pharmaceutical company developing a novel class of microbial bioenergetic inhibitors for the treatment of resistant and difficult to treat infections. Pravibismane, our first therapeutic candidate, has demonstrated in vitro broad spectrum, anti-bacterial efficacy against clinically relevant pathogens, including multiple priority pathogens or “superbugs” identified by the US Centers for Disease Control and Prevention (CDC). In addition, pravibismane also has demonstrated the ability to prevent and eradicate microbial biofilms. Pravibismane's antimicrobial / anti-biofilm activity has the potential to become a first-in-class, best-in-class clinical approach to treating serious and life-threatening infections.